Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
302 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
HIV-1 Infection - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'HIV-1 Infection - Pipeline Review, H2 2014', provides an overview of the HIV-1 Infection's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for HIV-1 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV-1 Infection and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of HIV-1 Infection - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for HIV-1 Infection and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the HIV-1 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the HIV-1 Infection pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for HIV-1 Infection - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding HIV-1 Infection pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 Introduction 6 HIV-1 Infection Overview 7 Therapeutics Development 8 HIV-1 Infection - Therapeutics under Development by Companies 10 HIV-1 Infection - Therapeutics under Investigation by Universities/Institutes 14 HIV-1 Infection - Pipeline Products Glance 18 HIV-1 Infection - Products under Development by Companies 22 HIV-1 Infection - Products under Investigation by Universities/Institutes 27 HIV-1 Infection - Companies Involved in Therapeutics Development 32 HIV-1 Infection - Therapeutics Assessment 72 Drug Profiles 84 HIV-1 Infection - Recent Pipeline Updates 249 HIV-1 Infection - Dormant Projects 274 HIV-1 Infection - Discontinued Products 278 HIV-1 Infection - Product Development Milestones 279 Appendix 287
List of Tables Number of Products under Development for HIV-1 Infection, H2 2014 22 Number of Products under Development for HIV-1 Infection - Comparative Analysis, H2 2014 23 Number of Products under Development by Companies, H2 2014 25 Number of Products under Development by Companies, H2 2014 (Contd..1) 26 Number of Products under Development by Companies, H2 2014 (Contd..2) 27 Number of Products under Investigation by Universities/Institutes, H2 2014 28 Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 30 Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 31 Comparative Analysis by Late Stage Development, H2 2014 32 Comparative Analysis by Clinical Stage Development, H2 2014 33 Comparative Analysis by Early Stage Development, H2 2014 34 Comparative Analysis by Unknown Stage Development, H2 2014 35 Products under Development by Companies, H2 2014 36 Products under Development by Companies, H2 2014 (Contd..1) 37 Products under Development by Companies, H2 2014 (Contd..2) 38 Products under Development by Companies, H2 2014 (Contd..3) 39 Products under Development by Companies, H2 2014 (Contd..4) 40 Products under Investigation by Universities/Institutes, H2 2014 41 Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 42 Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 43 Products under Investigation by Universities/Institutes, H2 2014 (Contd..3) 44 Products under Investigation by Universities/Institutes, H2 2014 (Contd..4) 45 HIV-1 Infection - Pipeline by AbbVie Inc., H2 2014 46 HIV-1 Infection - Pipeline by AlphaVax, Inc., H2 2014 47 HIV-1 Infection - Pipeline by AltraVax Inc., H2 2014 48 HIV-1 Infection - Pipeline by Amunix, Inc., H2 2014 49 HIV-1 Infection - Pipeline by Aphios Corporation, H2 2014 50 HIV-1 Infection - Pipeline by Argos Therapeutics, Inc., H2 2014 51 HIV-1 Infection - Pipeline by Bionor Pharma ASA, H2 2014 52 HIV-1 Infection - Pipeline by Biosantech SA, H2 2014 53 HIV-1 Infection - Pipeline by Boehringer Ingelheim GmbH, H2 2014 54 HIV-1 Infection - Pipeline by Bristol-Myers Squibb Company, H2 2014 55 HIV-1 Infection - Pipeline by Critical Outcome Technologies Inc., H2 2014 56 HIV-1 Infection - Pipeline by CytoDyn Inc., H2 2014 57 HIV-1 Infection - Pipeline by Enzo Biochem, Inc., H2 2014 58 HIV-1 Infection - Pipeline by FIT Biotech Oyj, H2 2014 59 HIV-1 Infection - Pipeline by GeneCure LLC, H2 2014 60 HIV-1 Infection - Pipeline by Gilead Sciences, Inc., H2 2014 61 HIV-1 Infection - Pipeline by GlaxoSmithKline plc, H2 2014 62 HIV-1 Infection - Pipeline by InnaVirVax SA, H2 2014 63 HIV-1 Infection - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014 64 HIV-1 Infection - Pipeline by Johnson & Johnson, H2 2014 65 HIV-1 Infection - Pipeline by Kaketsuken K.K., H2 2014 66 HIV-1 Infection - Pipeline by Koronis Pharma, Inc., H2 2014 67 HIV-1 Infection - Pipeline by Merck & Co., Inc., H2 2014 68 HIV-1 Infection - Pipeline by Mymetics Corporation, H2 2014 69 HIV-1 Infection - Pipeline by Myrexis, Inc., H2 2014 70 HIV-1 Infection - Pipeline by Oncovir, Inc., H2 2014 71 HIV-1 Infection - Pipeline by OyaGen Inc., H2 2014 72 HIV-1 Infection - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2014 73 HIV-1 Infection - Pipeline by Pfizer Inc., H2 2014 74 HIV-1 Infection - Pipeline by Pharis Biotec GmbH, H2 2014 75 HIV-1 Infection - Pipeline by RFS Pharma, LLC, H2 2014 76 HIV-1 Infection - Pipeline by Spider Biotech, H2 2014 77 HIV-1 Infection - Pipeline by TaiMed Biologics Inc., H2 2014 78 HIV-1 Infection - Pipeline by Takara Bio Inc., H2 2014 79 HIV-1 Infection - Pipeline by THERAVECTYS SA, H2 2014 80 HIV-1 Infection - Pipeline by Tobira Therapeutics, Inc., H2 2014 81 HIV-1 Infection - Pipeline by United Biomedical, Inc., H2 2014 82 HIV-1 Infection - Pipeline by Valens Therapeutics, Inc., H2 2014 83 HIV-1 Infection - Pipeline by Vichem Chemie Research Ltd., H2 2014 84 HIV-1 Infection - Pipeline by ViiV Healthcare, H2 2014 85 Assessment by Monotherapy Products, H2 2014 86 Assessment by Combination Products, H2 2014 87 Number of Products by Stage and Target, H2 2014 89 Number of Products by Stage and Mechanism of Action, H2 2014 92 Number of Products by Stage and Route of Administration, H2 2014 95 Number of Products by Stage and Molecule Type, H2 2014 97 HIV-1 Infection Therapeutics - Recent Pipeline Updates, H2 2014 263 HIV-1 Infection - Dormant Projects, H2 2014 288 HIV-1 Infection - Discontinued Products, H2 2014 292
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
